REPL News and Press, Replimune Group Inc. From 06/01/23

WOBURN, Mass., June 01, 2023 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ: REPL), a clinical stage biotechnology company pioneering the development of a novel portfolio of tumor-directed oncolytic immunotherapies, today announced that members from the Replimune management team will present i...

2023-05-26 11:56:25 ET Summary Even with new management in place, it is unlikely that a company will regain market share or turn profitable after it has lost its way. Carolina Dybeck Happe joined General Electric Company in March 2020 at a time when revenue had been declining shar...

WOBURN, Mass., May 25, 2023 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (Nasdaq: REPL), a clinical stage biotechnology company pioneering the development of a novel class of tumor-directed oncolytic immunotherapies, today announced multiple presentations at the 2023 American Society of Clinical Onc...

2023-05-18 08:59:08 ET Replimune Group press release ( NASDAQ: REPL ): FY GAAP EPS of -$2.99. As of March 31, 2023, cash, cash equivalents and short-term investments were $583.4 million, as compared to $395.7 million as of fiscal year end March 31, 2022...

Topline data disclosure from the registration-directed CERPASS clinical trial of RP1 combined with Libtayo ® (cemiplimab-rwlc) in cutaneous squamous cell carcinoma (CSCC) on track for Q3 2023 and Biologics License Application (BLA) submission on track for Q1 2024 Comple...

WOBURN, Mass., May 09, 2023 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ: REPL), a clinical stage biotechnology company pioneering the development of a novel portfolio of tumor-directed oncolytic immunotherapies, today announced that members from the Replimune management team will host inves...

2023-04-04 22:01:45 ET Summary Baker Brothers’ 13F portfolio value increased from $15.27B to $16.65B this quarter. Replimune Group stake was substantially increased this quarter. The top three positions are Seagen, Incyte Corporation, and BeiGene, and they add up to alm...

2023-03-09 17:28:11 ET Summary Replimune develops oncolytic immunotherapies for cancer, with RP1 (vusolimogene oderparepvec) being their lead product for treating cutaneous squamous cell carcinoma (CSCC). RP1 was given to 30 NMSC patients in the IGNYTE trial (single arm, open-labe...

Following four straight sessions of losses, oncology-focused biotech Replimune Group ( NASDAQ: REPL ) added ~7% on Monday after announcing a favorable response from the FDA regarding its Phase 2 trial CERPASS for lead asset RP1. The company has already completed patient enrollment...

Replimune Group press release ( NASDAQ: REPL ): Q3 GAAP EPS of -$0.69 beats by $0.08 . Cash and cash equivalents of $616.38M For further details see: Replimune Group GAAP EPS of -$0.69 beats by $0.08